Global Nonalcoholic Steatohepatitis (NASH) Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Nonalcoholic Steatohepatitis (NASH) market size was valued at USD 3152.9 million in 2023 and is forecast to a readjusted size of USD 41860 million by 2030 with a CAGR of 44.7% during review period.
Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
Non-alcoholic drinks, also known as mocktails or alcohol-free beverages, are beverages that do not contain any alcohol. These drinks are a popular choice for those who do not consume alcohol, including designated drivers, people who are underage, or individuals who wish to avoid alcohol for personal or health reasons. There are a wide variety of non-alcoholic drinks available, ranging from soft drinks to fresh juices, herbal infusions, and specialty mocktails. Some examples of non-alcoholic drinks include: 1. Soft Drinks: This category includes popular carbonated beverages like cola, lemon-lime sodas, ginger ale, and root beer. These drinks are often sweet and fizzy, providing a refreshing and enjoyable beverage option. 2. Fruit Juices: Freshly squeezed or packaged fruit juices, such as orange, apple, grapefruit, pineapple, or cranberry juice, are a common choice. These juices offer a natural and flavorful alternative to alcoholic beverages. 3. Smoothies: Made from a blend of fruits, vegetables, yogurt, and other ingredients, smoothies provide a nutritious and wholesome non-alcoholic option. They can be customized with various flavors and ingredients to suit individual preferences. 4. Herbal Infusions and Tea: Herbal teas and infusions, such as chamomile, peppermint, green tea, or hibiscus tea, are popular choices. These beverages are caffeine-free and often have relaxing or soothing properties. 5. Mocktails: These are non-alcoholic cocktails that mimic the flavors and presentation of traditional cocktails. They are typically made with a combination of juices, sodas, and garnishes, providing a fancy and enjoyable experience without the alcohol. 6. Sparkling Water: Carbonated water or mineral water with added flavors or fruit infusions is a refreshing and hydrating option. It is often consumed plain or mixed with juices or syrups. These non-alcoholic drinks offer a variety of flavors, textures, and options for those who prefer not to consume alcohol. They are a great way to enjoy a beverage while socializing or relaxing without the effects of alcohol.
The Global Info Research report includes an overview of the development of the Nonalcoholic Steatohepatitis (NASH) industry chain, the market status of Hospital Pharmacy (Obeticholic acid?OCA?, Selonsertib), Online Provider (Obeticholic acid?OCA?, Selonsertib), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Nonalcoholic Steatohepatitis (NASH).
Regionally, the report analyzes the Nonalcoholic Steatohepatitis (NASH) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Nonalcoholic Steatohepatitis (NASH) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Nonalcoholic Steatohepatitis (NASH) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Nonalcoholic Steatohepatitis (NASH) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Obeticholic acid?OCA?, Selonsertib).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Nonalcoholic Steatohepatitis (NASH) market.
Regional Analysis: The report involves examining the Nonalcoholic Steatohepatitis (NASH) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Nonalcoholic Steatohepatitis (NASH) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Nonalcoholic Steatohepatitis (NASH):
Company Analysis: Report covers individual Nonalcoholic Steatohepatitis (NASH) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Nonalcoholic Steatohepatitis (NASH) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacy, Online Provider).
Technology Analysis: Report covers specific technologies relevant to Nonalcoholic Steatohepatitis (NASH). It assesses the current state, advancements, and potential future developments in Nonalcoholic Steatohepatitis (NASH) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Nonalcoholic Steatohepatitis (NASH) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Nonalcoholic Steatohepatitis (NASH) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Nonalcoholic Steatohepatitis (NASH) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Nonalcoholic Steatohepatitis (NASH), with revenue, gross margin and global market share of Nonalcoholic Steatohepatitis (NASH) from 2019 to 2024.
Chapter 3, the Nonalcoholic Steatohepatitis (NASH) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Nonalcoholic Steatohepatitis (NASH) market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Nonalcoholic Steatohepatitis (NASH).
Chapter 13, to describe Nonalcoholic Steatohepatitis (NASH) research findings and conclusion.
Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
Non-alcoholic drinks, also known as mocktails or alcohol-free beverages, are beverages that do not contain any alcohol. These drinks are a popular choice for those who do not consume alcohol, including designated drivers, people who are underage, or individuals who wish to avoid alcohol for personal or health reasons. There are a wide variety of non-alcoholic drinks available, ranging from soft drinks to fresh juices, herbal infusions, and specialty mocktails. Some examples of non-alcoholic drinks include: 1. Soft Drinks: This category includes popular carbonated beverages like cola, lemon-lime sodas, ginger ale, and root beer. These drinks are often sweet and fizzy, providing a refreshing and enjoyable beverage option. 2. Fruit Juices: Freshly squeezed or packaged fruit juices, such as orange, apple, grapefruit, pineapple, or cranberry juice, are a common choice. These juices offer a natural and flavorful alternative to alcoholic beverages. 3. Smoothies: Made from a blend of fruits, vegetables, yogurt, and other ingredients, smoothies provide a nutritious and wholesome non-alcoholic option. They can be customized with various flavors and ingredients to suit individual preferences. 4. Herbal Infusions and Tea: Herbal teas and infusions, such as chamomile, peppermint, green tea, or hibiscus tea, are popular choices. These beverages are caffeine-free and often have relaxing or soothing properties. 5. Mocktails: These are non-alcoholic cocktails that mimic the flavors and presentation of traditional cocktails. They are typically made with a combination of juices, sodas, and garnishes, providing a fancy and enjoyable experience without the alcohol. 6. Sparkling Water: Carbonated water or mineral water with added flavors or fruit infusions is a refreshing and hydrating option. It is often consumed plain or mixed with juices or syrups. These non-alcoholic drinks offer a variety of flavors, textures, and options for those who prefer not to consume alcohol. They are a great way to enjoy a beverage while socializing or relaxing without the effects of alcohol.
The Global Info Research report includes an overview of the development of the Nonalcoholic Steatohepatitis (NASH) industry chain, the market status of Hospital Pharmacy (Obeticholic acid?OCA?, Selonsertib), Online Provider (Obeticholic acid?OCA?, Selonsertib), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Nonalcoholic Steatohepatitis (NASH).
Regionally, the report analyzes the Nonalcoholic Steatohepatitis (NASH) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Nonalcoholic Steatohepatitis (NASH) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Nonalcoholic Steatohepatitis (NASH) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Nonalcoholic Steatohepatitis (NASH) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Obeticholic acid?OCA?, Selonsertib).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Nonalcoholic Steatohepatitis (NASH) market.
Regional Analysis: The report involves examining the Nonalcoholic Steatohepatitis (NASH) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Nonalcoholic Steatohepatitis (NASH) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Nonalcoholic Steatohepatitis (NASH):
Company Analysis: Report covers individual Nonalcoholic Steatohepatitis (NASH) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Nonalcoholic Steatohepatitis (NASH) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacy, Online Provider).
Technology Analysis: Report covers specific technologies relevant to Nonalcoholic Steatohepatitis (NASH). It assesses the current state, advancements, and potential future developments in Nonalcoholic Steatohepatitis (NASH) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Nonalcoholic Steatohepatitis (NASH) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Nonalcoholic Steatohepatitis (NASH) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Obeticholic acid?OCA?
- Selonsertib
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- AstraZeneca
- Arena Pharmaceuticals
- GSK
- Novo Nordisk
- Roche
- Vivus
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Nonalcoholic Steatohepatitis (NASH) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Nonalcoholic Steatohepatitis (NASH), with revenue, gross margin and global market share of Nonalcoholic Steatohepatitis (NASH) from 2019 to 2024.
Chapter 3, the Nonalcoholic Steatohepatitis (NASH) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Nonalcoholic Steatohepatitis (NASH) market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Nonalcoholic Steatohepatitis (NASH).
Chapter 13, to describe Nonalcoholic Steatohepatitis (NASH) research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Nonalcoholic Steatohepatitis (NASH)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Nonalcoholic Steatohepatitis (NASH) by Type
1.3.1 Overview: Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type in 2023
1.3.3 Obeticholic acid?OCA?
1.3.4 Selonsertib
1.4 Global Nonalcoholic Steatohepatitis (NASH) Market by Application
1.4.1 Overview: Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital Pharmacy
1.4.3 Online Provider
1.4.4 Retail Pharmacy
1.5 Global Nonalcoholic Steatohepatitis (NASH) Market Size & Forecast
1.6 Global Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast by Region
1.6.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region, (2019-2030)
1.6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.6 South America Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.1.4 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Arena Pharmaceuticals
2.2.1 Arena Pharmaceuticals Details
2.2.2 Arena Pharmaceuticals Major Business
2.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.2.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Arena Pharmaceuticals Recent Developments and Future Plans
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.3.4 GSK Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 GSK Recent Developments and Future Plans
2.4 Novo Nordisk
2.4.1 Novo Nordisk Details
2.4.2 Novo Nordisk Major Business
2.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.4.4 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novo Nordisk Recent Developments and Future Plans
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business
2.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.5.4 Roche Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Roche Recent Developments and Future Plans
2.6 Vivus
2.6.1 Vivus Details
2.6.2 Vivus Major Business
2.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.6.4 Vivus Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Vivus Recent Developments and Future Plans
2.7 Arisaph Pharmaceuticals
2.7.1 Arisaph Pharmaceuticals Details
2.7.2 Arisaph Pharmaceuticals Major Business
2.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.7.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Arisaph Pharmaceuticals Recent Developments and Future Plans
2.8 Cempra Pharmaceuticals
2.8.1 Cempra Pharmaceuticals Details
2.8.2 Cempra Pharmaceuticals Major Business
2.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.8.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Cempra Pharmaceuticals Recent Developments and Future Plans
2.9 Galectin Therapeutics
2.9.1 Galectin Therapeutics Details
2.9.2 Galectin Therapeutics Major Business
2.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.9.4 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Galectin Therapeutics Recent Developments and Future Plans
2.10 Galmed Pharmaceuticals
2.10.1 Galmed Pharmaceuticals Details
2.10.2 Galmed Pharmaceuticals Major Business
2.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.10.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Galmed Pharmaceuticals Recent Developments and Future Plans
2.11 Genfit
2.11.1 Genfit Details
2.11.2 Genfit Major Business
2.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.11.4 Genfit Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Genfit Recent Developments and Future Plans
2.12 Gilead
2.12.1 Gilead Details
2.12.2 Gilead Major Business
2.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.12.4 Gilead Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Gilead Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Nonalcoholic Steatohepatitis (NASH) by Company Revenue
3.2.2 Top 3 Nonalcoholic Steatohepatitis (NASH) Players Market Share in 2023
3.2.3 Top 6 Nonalcoholic Steatohepatitis (NASH) Players Market Share in 2023
3.3 Nonalcoholic Steatohepatitis (NASH) Market: Overall Company Footprint Analysis
3.3.1 Nonalcoholic Steatohepatitis (NASH) Market: Region Footprint
3.3.2 Nonalcoholic Steatohepatitis (NASH) Market: Company Product Type Footprint
3.3.3 Nonalcoholic Steatohepatitis (NASH) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption Value and Market Share by Type (2019-2024)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2024)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
6.3.2 United States Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
6.3.3 Canada Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
6.3.4 Mexico Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
7.2 Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
7.3.2 Germany Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.3 France Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.5 Russia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.6 Italy Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region
8.3.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2019-2030)
8.3.2 China Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.4 South Korea Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.5 India Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.7 Australia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
9.2 South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
9.3 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
9.3.1 South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
9.3.2 Brazil Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
9.3.3 Argentina Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
10.3.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
10.3.2 Turkey Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
10.3.4 UAE Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Nonalcoholic Steatohepatitis (NASH) Market Drivers
11.2 Nonalcoholic Steatohepatitis (NASH) Market Restraints
11.3 Nonalcoholic Steatohepatitis (NASH) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Nonalcoholic Steatohepatitis (NASH) Industry Chain
12.2 Nonalcoholic Steatohepatitis (NASH) Upstream Analysis
12.3 Nonalcoholic Steatohepatitis (NASH) Midstream Analysis
12.4 Nonalcoholic Steatohepatitis (NASH) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Nonalcoholic Steatohepatitis (NASH)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Nonalcoholic Steatohepatitis (NASH) by Type
1.3.1 Overview: Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type in 2023
1.3.3 Obeticholic acid?OCA?
1.3.4 Selonsertib
1.4 Global Nonalcoholic Steatohepatitis (NASH) Market by Application
1.4.1 Overview: Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital Pharmacy
1.4.3 Online Provider
1.4.4 Retail Pharmacy
1.5 Global Nonalcoholic Steatohepatitis (NASH) Market Size & Forecast
1.6 Global Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast by Region
1.6.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region, (2019-2030)
1.6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.6 South America Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.1.4 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Arena Pharmaceuticals
2.2.1 Arena Pharmaceuticals Details
2.2.2 Arena Pharmaceuticals Major Business
2.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.2.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Arena Pharmaceuticals Recent Developments and Future Plans
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.3.4 GSK Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 GSK Recent Developments and Future Plans
2.4 Novo Nordisk
2.4.1 Novo Nordisk Details
2.4.2 Novo Nordisk Major Business
2.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.4.4 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novo Nordisk Recent Developments and Future Plans
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business
2.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.5.4 Roche Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Roche Recent Developments and Future Plans
2.6 Vivus
2.6.1 Vivus Details
2.6.2 Vivus Major Business
2.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.6.4 Vivus Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Vivus Recent Developments and Future Plans
2.7 Arisaph Pharmaceuticals
2.7.1 Arisaph Pharmaceuticals Details
2.7.2 Arisaph Pharmaceuticals Major Business
2.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.7.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Arisaph Pharmaceuticals Recent Developments and Future Plans
2.8 Cempra Pharmaceuticals
2.8.1 Cempra Pharmaceuticals Details
2.8.2 Cempra Pharmaceuticals Major Business
2.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.8.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Cempra Pharmaceuticals Recent Developments and Future Plans
2.9 Galectin Therapeutics
2.9.1 Galectin Therapeutics Details
2.9.2 Galectin Therapeutics Major Business
2.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.9.4 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Galectin Therapeutics Recent Developments and Future Plans
2.10 Galmed Pharmaceuticals
2.10.1 Galmed Pharmaceuticals Details
2.10.2 Galmed Pharmaceuticals Major Business
2.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.10.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Galmed Pharmaceuticals Recent Developments and Future Plans
2.11 Genfit
2.11.1 Genfit Details
2.11.2 Genfit Major Business
2.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.11.4 Genfit Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Genfit Recent Developments and Future Plans
2.12 Gilead
2.12.1 Gilead Details
2.12.2 Gilead Major Business
2.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Product and Solutions
2.12.4 Gilead Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Gilead Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Nonalcoholic Steatohepatitis (NASH) by Company Revenue
3.2.2 Top 3 Nonalcoholic Steatohepatitis (NASH) Players Market Share in 2023
3.2.3 Top 6 Nonalcoholic Steatohepatitis (NASH) Players Market Share in 2023
3.3 Nonalcoholic Steatohepatitis (NASH) Market: Overall Company Footprint Analysis
3.3.1 Nonalcoholic Steatohepatitis (NASH) Market: Region Footprint
3.3.2 Nonalcoholic Steatohepatitis (NASH) Market: Company Product Type Footprint
3.3.3 Nonalcoholic Steatohepatitis (NASH) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption Value and Market Share by Type (2019-2024)
4.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2024)
5.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
6.2 North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
6.3.2 United States Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
6.3.3 Canada Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
6.3.4 Mexico Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
7.2 Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
7.3.2 Germany Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.3 France Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.5 Russia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
7.3.6 Italy Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region
8.3.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2019-2030)
8.3.2 China Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.4 South Korea Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.5 India Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
8.3.7 Australia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
9.2 South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
9.3 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
9.3.1 South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
9.3.2 Brazil Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
9.3.3 Argentina Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
10.3.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2030)
10.3.2 Turkey Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
10.3.4 UAE Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Nonalcoholic Steatohepatitis (NASH) Market Drivers
11.2 Nonalcoholic Steatohepatitis (NASH) Market Restraints
11.3 Nonalcoholic Steatohepatitis (NASH) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Nonalcoholic Steatohepatitis (NASH) Industry Chain
12.2 Nonalcoholic Steatohepatitis (NASH) Upstream Analysis
12.3 Nonalcoholic Steatohepatitis (NASH) Midstream Analysis
12.4 Nonalcoholic Steatohepatitis (NASH) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2025-2030) & (USD Million)
Table 5. AstraZeneca Company Information, Head Office, and Major Competitors
Table 6. AstraZeneca Major Business
Table 7. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 8. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. AstraZeneca Recent Developments and Future Plans
Table 10. Arena Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Arena Pharmaceuticals Major Business
Table 12. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 13. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Arena Pharmaceuticals Recent Developments and Future Plans
Table 15. GSK Company Information, Head Office, and Major Competitors
Table 16. GSK Major Business
Table 17. GSK Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 18. GSK Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. GSK Recent Developments and Future Plans
Table 20. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 21. Novo Nordisk Major Business
Table 22. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 23. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Novo Nordisk Recent Developments and Future Plans
Table 25. Roche Company Information, Head Office, and Major Competitors
Table 26. Roche Major Business
Table 27. Roche Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 28. Roche Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Roche Recent Developments and Future Plans
Table 30. Vivus Company Information, Head Office, and Major Competitors
Table 31. Vivus Major Business
Table 32. Vivus Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 33. Vivus Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Vivus Recent Developments and Future Plans
Table 35. Arisaph Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Arisaph Pharmaceuticals Major Business
Table 37. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 38. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Arisaph Pharmaceuticals Recent Developments and Future Plans
Table 40. Cempra Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 41. Cempra Pharmaceuticals Major Business
Table 42. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 43. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Cempra Pharmaceuticals Recent Developments and Future Plans
Table 45. Galectin Therapeutics Company Information, Head Office, and Major Competitors
Table 46. Galectin Therapeutics Major Business
Table 47. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 48. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Galectin Therapeutics Recent Developments and Future Plans
Table 50. Galmed Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Galmed Pharmaceuticals Major Business
Table 52. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 53. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Galmed Pharmaceuticals Recent Developments and Future Plans
Table 55. Genfit Company Information, Head Office, and Major Competitors
Table 56. Genfit Major Business
Table 57. Genfit Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 58. Genfit Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Genfit Recent Developments and Future Plans
Table 60. Gilead Company Information, Head Office, and Major Competitors
Table 61. Gilead Major Business
Table 62. Gilead Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 63. Gilead Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Gilead Recent Developments and Future Plans
Table 65. Global Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) by Players (2019-2024)
Table 66. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players (2019-2024)
Table 67. Breakdown of Nonalcoholic Steatohepatitis (NASH) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Nonalcoholic Steatohepatitis (NASH), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 69. Head Office of Key Nonalcoholic Steatohepatitis (NASH) Players
Table 70. Nonalcoholic Steatohepatitis (NASH) Market: Company Product Type Footprint
Table 71. Nonalcoholic Steatohepatitis (NASH) Market: Company Product Application Footprint
Table 72. Nonalcoholic Steatohepatitis (NASH) New Market Entrants and Barriers to Market Entry
Table 73. Nonalcoholic Steatohepatitis (NASH) Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value (USD Million) by Type (2019-2024)
Table 75. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Share by Type (2019-2024)
Table 76. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Forecast by Type (2025-2030)
Table 77. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024)
Table 78. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Forecast by Application (2025-2030)
Table 79. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 80. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 81. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 82. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 83. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 84. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 85. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 86. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 87. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 88. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 89. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 90. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 91. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 92. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 93. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 94. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 95. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2019-2024) & (USD Million)
Table 96. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2025-2030) & (USD Million)
Table 97. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 98. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 99. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 100. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 101. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 102. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 103. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 104. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 105. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 106. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 107. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 108. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 109. Nonalcoholic Steatohepatitis (NASH) Raw Material
Table 110. Key Suppliers of Nonalcoholic Steatohepatitis (NASH) Raw Materials
Table 1. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2025-2030) & (USD Million)
Table 5. AstraZeneca Company Information, Head Office, and Major Competitors
Table 6. AstraZeneca Major Business
Table 7. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 8. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. AstraZeneca Recent Developments and Future Plans
Table 10. Arena Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Arena Pharmaceuticals Major Business
Table 12. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 13. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Arena Pharmaceuticals Recent Developments and Future Plans
Table 15. GSK Company Information, Head Office, and Major Competitors
Table 16. GSK Major Business
Table 17. GSK Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 18. GSK Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. GSK Recent Developments and Future Plans
Table 20. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 21. Novo Nordisk Major Business
Table 22. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 23. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Novo Nordisk Recent Developments and Future Plans
Table 25. Roche Company Information, Head Office, and Major Competitors
Table 26. Roche Major Business
Table 27. Roche Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 28. Roche Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Roche Recent Developments and Future Plans
Table 30. Vivus Company Information, Head Office, and Major Competitors
Table 31. Vivus Major Business
Table 32. Vivus Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 33. Vivus Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Vivus Recent Developments and Future Plans
Table 35. Arisaph Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Arisaph Pharmaceuticals Major Business
Table 37. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 38. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Arisaph Pharmaceuticals Recent Developments and Future Plans
Table 40. Cempra Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 41. Cempra Pharmaceuticals Major Business
Table 42. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 43. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Cempra Pharmaceuticals Recent Developments and Future Plans
Table 45. Galectin Therapeutics Company Information, Head Office, and Major Competitors
Table 46. Galectin Therapeutics Major Business
Table 47. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 48. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Galectin Therapeutics Recent Developments and Future Plans
Table 50. Galmed Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Galmed Pharmaceuticals Major Business
Table 52. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 53. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Galmed Pharmaceuticals Recent Developments and Future Plans
Table 55. Genfit Company Information, Head Office, and Major Competitors
Table 56. Genfit Major Business
Table 57. Genfit Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 58. Genfit Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Genfit Recent Developments and Future Plans
Table 60. Gilead Company Information, Head Office, and Major Competitors
Table 61. Gilead Major Business
Table 62. Gilead Nonalcoholic Steatohepatitis (NASH) Product and Solutions
Table 63. Gilead Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Gilead Recent Developments and Future Plans
Table 65. Global Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) by Players (2019-2024)
Table 66. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players (2019-2024)
Table 67. Breakdown of Nonalcoholic Steatohepatitis (NASH) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 68. Market Position of Players in Nonalcoholic Steatohepatitis (NASH), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 69. Head Office of Key Nonalcoholic Steatohepatitis (NASH) Players
Table 70. Nonalcoholic Steatohepatitis (NASH) Market: Company Product Type Footprint
Table 71. Nonalcoholic Steatohepatitis (NASH) Market: Company Product Application Footprint
Table 72. Nonalcoholic Steatohepatitis (NASH) New Market Entrants and Barriers to Market Entry
Table 73. Nonalcoholic Steatohepatitis (NASH) Mergers, Acquisition, Agreements, and Collaborations
Table 74. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value (USD Million) by Type (2019-2024)
Table 75. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Share by Type (2019-2024)
Table 76. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Forecast by Type (2025-2030)
Table 77. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024)
Table 78. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Forecast by Application (2025-2030)
Table 79. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 80. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 81. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 82. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 83. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 84. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 85. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 86. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 87. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 88. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 89. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 90. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 91. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 92. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 93. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 94. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 95. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2019-2024) & (USD Million)
Table 96. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value by Region (2025-2030) & (USD Million)
Table 97. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 98. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 99. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 100. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 101. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 102. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 103. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2019-2024) & (USD Million)
Table 104. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type (2025-2030) & (USD Million)
Table 105. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2019-2024) & (USD Million)
Table 106. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Application (2025-2030) & (USD Million)
Table 107. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2019-2024) & (USD Million)
Table 108. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value by Country (2025-2030) & (USD Million)
Table 109. Nonalcoholic Steatohepatitis (NASH) Raw Material
Table 110. Key Suppliers of Nonalcoholic Steatohepatitis (NASH) Raw Materials
LIST OF FIGURES
Figure 1. Nonalcoholic Steatohepatitis (NASH) Picture
Figure 2. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type in 2023
Figure 4. Obeticholic acid?OCA?
Figure 5. Selonsertib
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application in 2023
Figure 8. Hospital Pharmacy Picture
Figure 9. Online Provider Picture
Figure 10. Retail Pharmacy Picture
Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Market Nonalcoholic Steatohepatitis (NASH) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 14. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Region (2019-2030)
Figure 15. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Region in 2023
Figure 16. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 17. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 18. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 19. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 20. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 21. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players in 2023
Figure 22. Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 23. Global Top 3 Players Nonalcoholic Steatohepatitis (NASH) Market Share in 2023
Figure 24. Global Top 6 Players Nonalcoholic Steatohepatitis (NASH) Market Share in 2023
Figure 25. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Share by Type (2019-2024)
Figure 26. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Type (2025-2030)
Figure 27. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Share by Application (2019-2024)
Figure 28. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Application (2025-2030)
Figure 29. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 30. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 31. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 32. United States Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 33. Canada Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 34. Mexico Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 35. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 36. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 37. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 38. Germany Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 39. France Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 40. United Kingdom Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 41. Russia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 42. Italy Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 43. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 44. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 45. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Region (2019-2030)
Figure 46. China Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 47. Japan Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 48. South Korea Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 49. India Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 50. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 51. Australia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 52. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 53. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 54. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 55. Brazil Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 56. Argentina Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 57. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 58. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 59. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 60. Turkey Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 61. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 62. UAE Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 63. Nonalcoholic Steatohepatitis (NASH) Market Drivers
Figure 64. Nonalcoholic Steatohepatitis (NASH) Market Restraints
Figure 65. Nonalcoholic Steatohepatitis (NASH) Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Nonalcoholic Steatohepatitis (NASH) in 2023
Figure 68. Manufacturing Process Analysis of Nonalcoholic Steatohepatitis (NASH)
Figure 69. Nonalcoholic Steatohepatitis (NASH) Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Nonalcoholic Steatohepatitis (NASH) Picture
Figure 2. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type in 2023
Figure 4. Obeticholic acid?OCA?
Figure 5. Selonsertib
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application in 2023
Figure 8. Hospital Pharmacy Picture
Figure 9. Online Provider Picture
Figure 10. Retail Pharmacy Picture
Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Market Nonalcoholic Steatohepatitis (NASH) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 14. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Region (2019-2030)
Figure 15. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Region in 2023
Figure 16. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 17. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 18. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 19. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 20. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 21. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players in 2023
Figure 22. Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 23. Global Top 3 Players Nonalcoholic Steatohepatitis (NASH) Market Share in 2023
Figure 24. Global Top 6 Players Nonalcoholic Steatohepatitis (NASH) Market Share in 2023
Figure 25. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Share by Type (2019-2024)
Figure 26. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Type (2025-2030)
Figure 27. Global Nonalcoholic Steatohepatitis (NASH) Consumption Value Share by Application (2019-2024)
Figure 28. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Application (2025-2030)
Figure 29. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 30. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 31. North America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 32. United States Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 33. Canada Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 34. Mexico Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 35. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 36. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 37. Europe Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 38. Germany Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 39. France Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 40. United Kingdom Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 41. Russia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 42. Italy Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 43. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 44. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 45. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Region (2019-2030)
Figure 46. China Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 47. Japan Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 48. South Korea Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 49. India Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 50. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 51. Australia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 52. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 53. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 54. South America Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 55. Brazil Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 56. Argentina Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 57. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Type (2019-2030)
Figure 58. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Application (2019-2030)
Figure 59. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Consumption Value Market Share by Country (2019-2030)
Figure 60. Turkey Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 61. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 62. UAE Nonalcoholic Steatohepatitis (NASH) Consumption Value (2019-2030) & (USD Million)
Figure 63. Nonalcoholic Steatohepatitis (NASH) Market Drivers
Figure 64. Nonalcoholic Steatohepatitis (NASH) Market Restraints
Figure 65. Nonalcoholic Steatohepatitis (NASH) Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Nonalcoholic Steatohepatitis (NASH) in 2023
Figure 68. Manufacturing Process Analysis of Nonalcoholic Steatohepatitis (NASH)
Figure 69. Nonalcoholic Steatohepatitis (NASH) Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
